Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 1 2Phase 2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Other solid neoplasm 2Gynecologic 2Breast 1

Conditions

Leukemia, Myeloid, Acute 34Leukemia 26Lymphoma, Non-Hodgkin 23Lymphoma 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Recurrence 19Leukemia, Lymphocytic, Chronic, B-Cell 19Myelodysplastic Syndromes 18Hematologic Neoplasms 18Melanoma 16Neoplasm Metastasis 15Lymphoma, B-Cell 14Multiple Myeloma 12Pancreatic Neoplasms 11Hodgkin Disease 11Stomach Neoplasms 10Ovarian Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Breast Neoplasms 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma, Mantle-Cell 7Lymphoma, Follicular 7Uterine Cervical Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Neoplasms, Plasma Cell 5Kidney Neoplasms 5Burkitt Lymphoma 5Myeloproliferative Disorders 4

Interventions

Gemcitabine 11pembrolizumab 8Cisplatin 8Oxaliplatin 4fludarabine 3durvalumab 3Nivolumab 3Cyclophosphamide 3130-nm albumin-bound paclitaxel 3Specimen Handling 2Radiation 2Ipilimumab 2Drug Therapy 2Capecitabine 2Biopsy 2tremelimumab 1trametinib 1tivozanib 1tislelizumab 1silmitasertib 1pertuzumab 1peposertib 1pemigatinib 1olutasidenib 1lenvatinib 1inositol trispyrophosphate 1futibatinib 1enasidenib 1devimistat 1derazantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Cholangiocarcinoma × fludarabine × Clear all
NCT07641036 2026-06-11

DUET-BTC

Beijing Biotech

Phase 1/2 Recruiting
30 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡